FES anticorps (N-Term)
-
- Antigène Voir toutes FES Anticorps
- FES (Feline Sarcoma Oncogene (FES))
-
Épitope
- N-Term
-
Reactivité
- Humain, Souris, Rat
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp FES est non-conjugé
-
Application
- Western Blotting (WB)
- Specificité
- FES antibody was raised against the N terminal of FES
- Purification
- Affinity purified
- Immunogène
- FES antibody was raised using the N terminal of FES corresponding to a region with amino acids ARDSAQAKRKYQEASKDKDRDKAKDKYVRSLWKLFAHHNRYVLGVRAAQL
- Top Product
- Discover our top product FES Anticorps primaire
-
-
- Indications d'application
-
WB: 1 µg/mL
Optimal conditions should be determined by the investigator. - Commentaires
-
FES Blocking Peptide, catalog no. 33R-1466, is also available for use as a blocking control in assays to test for specificity of this FES antibody
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of FES antibody in PBS
- Concentration
- Lot specific
- Buffer
- PBS
- Conseil sur la manipulation
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. - Stock
- 4 °C/-20 °C
- Stockage commentaire
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
- Antigène
- FES (Feline Sarcoma Oncogene (FES))
- Autre désignation
- FES (FES Produits)
- Synonymes
- anticorps FPS, anticorps RGD1564385, anticorps AI586313, anticorps BB137047, anticorps c-fes, anticorps FES, anticorps c-fps, anticorps FES proto-oncogene, tyrosine kinase, anticorps feline sarcoma oncogene, anticorps FES, anticorps Fes, anticorps fes
- Sujet
- FES is the human cellular counterpart of a feline sarcoma retrovirus protein with transforming capabilities. FES has tyrosine-specific protein kinase activity and that activity is required for maintenance of cellular transformation. Its chromosomal location has linked it to a specific translocation event identified in patients with acute promyelocytic leukemia but it is also involved in normal hematopoiesis.
- Poids moléculaire
- 93 kDa (MW of target protein)
- Pathways
- Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Signaling Events mediated by VEGFR1 and VEGFR2
-